Adrenal suppression and infection, child, adolescents, elderly, history of TB and steroid myopathy, hypertension, recent MI, CHF, liver failure, renal impairment, DM and glaucoma (including family history), osteoporosis, corneal perforation, severe affective disorders, epilepsy, peptic ulcer, hypothyroidism, pregnancy and lactation.
Indication
Allergic and inflammatory disorders, Duchenne muscular dystrophy
Contra Indication
Systemic infection; live virus vaccines in those receiving immunosuppressive doses.
Dose
N/A
Side Effect
GI disturbances, musculoskeletal, endocrine, neuropsychiatric, ophthalmic, fluid and electrolyte disturbances; susceptible to infection, impaired healing, hypersensitivity, skin atrophy, striae, telangiectasia, acne, myocardial rupture following recent MI, thromboembolism.
Pregnancy Category
Name :
Not Classified
Description
FDA has not yet classified the drug into a specified pregnancy category.
Mode of Action
Deflazacort, derived from prednisolone, is a corticosteroid with mainly glucocorticoid activity. An anti-inflammatory dose of 6 mg deflazacort is equiv to 5 mg prednisolone.
Pregnancy
Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism
Lactation
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects
Consider the developmental and health benefits of breastfeeding along with the mother?s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition
Adult Dose
Oral
Allergic and inflammatory disorders
Adult:
Usual maintenance 3?18 mg daily (acute disorders, initially up to 120 mg daily).
Rheumatoid arthritis: 3-18 mg/day
Bronchial asthma: 48-72 mg/day.
Duchenne Muscular Dystrophy
Indicated for Duchenne muscular dystrophy (DMD)
0.9 mg/kg/day PO qDay
Hepatic impairment
Mild or moderate: No dose adjustment required
Severe: Not studied
Child Dose
Oral
Allergic and inflammatory disorders
Child 1 month?11 years: 0.25?1.5 mg/kg daily or on alternate days; up to 2.4 mg/kg (max.120 mg) daily in emergency situations.
Child 12?17 years: 3?18 mg daily or on alternate days; up to 2.4 mg/kg (max. 120 mg) daily in emergency situations.
Renal Dose
Renal impairment
Mild, moderate, or severe: No dose adjustment required
Administration
May take with or without food
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.